Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 8,499

Sort by:

Enterobacteriaceae Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Enterobacteriaceae Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Enterobacteriaceae Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Ente...

April 2021 95 pages

Enterococcus Faecium Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Enterococcus Faecium Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Enterococcus Faecium Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the...

April 2021 45 pages

Enterococcus Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Enterococcus Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Enterococcus Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Enterococcus Inf...

April 2021 45 pages

Enterovirus Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Enterovirus Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Enterovirus Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Enterovirus Infect...

April 2021 55 pages

Envelope Protein M (Matrix Protein) - Drugs in Development, 2021

US$ 3,000.00

Envelope Protein M (Matrix Protein) - Drugs in Development, 2021 SUMMARY Envelope Protein M (Matrix Protein) - Drugs in Development, 2021 provides in depth analysis on Envelope Protein M (Matrix Prote...

April 2021 30 pages

Ependymoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Ependymoma (Oncology) - Drugs in Development, 2021 SUMMARY Ependymoma (Oncology) - Drugs in Development, 2021 provides an overview of the Ependymoma pipeline landscape. The report provides comprehensi...

April 2021 55 pages

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Drugs in Development, 2021

US$ 3,000.00

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Drugs in Development, 2021 SUMMARY Ephrin Type A Receptor 2 (Epithelial Cell Kinase...

April 2021 35 pages

Epidermal Growth Factor (EGF) - Drugs in Development, 2021

US$ 3,000.00

Epidermal Growth Factor (EGF) - Drugs in Development, 2021 SUMMARY Epidermal Growth Factor (EGF) - Drugs in Development, 2021 provides in depth analysis on Epidermal Growth Factor (EGF) targeted pipel...

April 2021 35 pages

Epidermal Growth Factor Receptor (EC 2.7.10.1) - Drugs in Development, 2021

US$ 3,000.00

Epidermal Growth Factor Receptor (EC 2.7.10.1) - Drugs in Development, 2021 SUMMARY Epidermal Growth Factor Receptor (EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis on Epidermal...

April 2021 35 pages

Epileptic Encephalopathy (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Epileptic Encephalopathy (Central Nervous System) - Drugs in Development, 2021 SUMMARY Epileptic Encephalopathy (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Epilep...

April 2021 40 pages

Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Epithelial Ovarian Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Epithelial Ovarian Cancer pipeli...

April 2021 300 pages

Epithelial Sodium Channel (ENaC or SCNN1) - Drugs in Development, 2021

US$ 3,000.00

Epithelial Sodium Channel (ENaC or SCNN1) - Drugs in Development, 2021 SUMMARY Epithelial Sodium Channel (ENaC or SCNN1) - Drugs in Development, 2021 provides in depth analysis on Epithelial Sodium Ch...

April 2021 40 pages

Esophageal Squamous Cell Carcinoma (ESCC) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Esophageal Squamous Cell Carcinoma (ESCC) (Oncology) - Drugs in Development, 2021 SUMMARY Esophageal Squamous Cell Carcinoma (ESCC) (Oncology) - Drugs in Development, 2021 provides an overview of the...

April 2021 110 pages

Essential Tremor (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Essential Tremor (Central Nervous System) - Drugs in Development, 2021 SUMMARY Essential Tremor (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Essential Tremor pipel...

April 2021 40 pages

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drugs in Development, 2021

US$ 3,000.00

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drugs in Development, 2021 SUMMARY Estrogen Receptor (ER Alpha or Estradiol Recep...

April 2021 60 pages

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Drugs in Development, 2021

US$ 3,000.00

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Drugs in Development, 2021 SUMMARY Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa...

April 2021 35 pages

Excitatory Amino Acid Transporter 2 (Glutamate/Aspartate Transporter II or Sodium Dependent Glutamate/Aspartate Transporter 2 or Solute Carrier Family 1 Member 2 or SLC1A2) - Drugs in Development, 2021

US$ 3,000.00

Excitatory Amino Acid Transporter 2 (Glutamate/Aspartate Transporter II or Sodium Dependent Glutamate/Aspartate Transporter 2 or Solute Carrier Family 1 Member 2 or SLC1A2) - Drugs in Development, 202...

April 2021 30 pages

Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18) - Drugs in Development, 2021

US$ 3,000.00

Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18) - Drugs in Development, 2021 SUMMARY Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18) - Drugs in Deve...

April 2021 50 pages

Exocrine Pancreatic Insufficiency (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Exocrine Pancreatic Insufficiency (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Exocrine Pancreatic Insufficiency (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the...

April 2021 30 pages

Extrahepatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Extrahepatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Extrahepatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Extrahepatic Bile Duct C...

April 2021 40 pages

Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) (Oncology) - Drugs in Development, 2021 SUMMARY Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associate...

April 2021 60 pages

Facioscapulohumeral Muscular Dystrophy (FSHD) (Musculoskeletal Disorders) - Drugs in Development, 2021

US$ 2,000.00

Facioscapulohumeral Muscular Dystrophy (FSHD) (Musculoskeletal Disorders) - Drugs in Development, 2021 SUMMARY Facioscapulohumeral Muscular Dystrophy (FSHD) (Musculoskeletal Disorders) - Drugs in Deve...

April 2021 40 pages

FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase (Decaprenylphospho-Beta-D-Ribofuranose 2-Dehydrogenase or Decaprenylphosphoryl-Beta-D-Ribofuranose 2'-Epimerase 1 or dprE1 or EC 1.1.98.3) - Drugs in Development, 2021

US$ 3,000.00

FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase (Decaprenylphospho-Beta-D-Ribofuranose 2-Dehydrogenase or Decaprenylphosphoryl-Beta-D-Ribofuranose 2'-Epimerase 1 or dprE1 or EC 1.1.98...

April 2021 30 pages

Familial Amyloid Cardiomyopathy (Metabolic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Familial Amyloid Cardiomyopathy (Metabolic Disorders) - Drugs in Development, 2021 SUMMARY Familial Amyloid Cardiomyopathy (Metabolic Disorders) - Drugs in Development, 2021 provides an overview of th...

April 2021 30 pages

Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021 SUMMARY Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs i...

April 2021 35 pages

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021 SUMMARY Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) (Metabolic Disorder...

April 2021 30 pages

Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase or (2E,6E) Farnesyl Diphosphate Synthase or Dimethylallyltranstransferase or Geranyltranstransferase or FDPS or EC 2.5.1.10 or EC 2.5.1.1) - Drugs in Development, 2021

US$ 3,000.00

Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase or (2E,6E) Farnesyl Diphosphate Synthase or Dimethylallyltranstransferase or Geranyltranstransferase or FDPS or EC 2.5.1.10 or EC 2.5.1.1...

April 2021 35 pages

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Drugs in Development, 2021

US$ 3,000.00

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Drugs in Development, 2021 SUMMARY Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamid...

April 2021 45 pages

Fatty Liver Disease (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Fatty Liver Disease (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Fatty Liver Disease (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Fatty Liver Disease pipeline...

April 2021 40 pages

Fc Fragment Of IgG Low Affinity III Receptor (CD16 or FCGR3) - Drugs in Development, 2021

US$ 3,000.00

Fc Fragment Of IgG Low Affinity III Receptor (CD16 or FCGR3) - Drugs in Development, 2021 SUMMARY Fc Fragment Of IgG Low Affinity III Receptor (CD16 or FCGR3) - Drugs in Development, 2021 provides in...

April 2021 55 pages

Febrile Neutropenia (Hematological Disorders) - Drugs in Development, 2021

US$ 2,000.00

Febrile Neutropenia (Hematological Disorders) - Drugs in Development, 2021 SUMMARY Febrile Neutropenia (Hematological Disorders) - Drugs in Development, 2021 provides an overview of the Febrile Neutro...

April 2021 50 pages

Fecal Incontinence (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Fecal Incontinence (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Fecal Incontinence (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Fecal Incontinence pipeline la...

April 2021 30 pages

Fever (Other Diseases) - Drugs in Development, 2021

US$ 2,000.00

Fever (Other Diseases) - Drugs in Development, 2021 SUMMARY Fever (Other Diseases) - Drugs in Development, 2021 provides an overview of the Fever pipeline landscape. The report provides comprehensive...

April 2021 35 pages

Fibrinogen (Coagulation Factor I or FG) - Drugs in Development, 2021

US$ 3,000.00

Fibrinogen (Coagulation Factor I or FG) - Drugs in Development, 2021 SUMMARY Fibrinogen (Coagulation Factor I or FG) - Drugs in Development, 2021 provides in depth analysis on Fibrinogen (Coagulation...

April 2021 40 pages

Fibroblast Growth Factor 21 (FGF21) - Drugs in Development, 2021

US$ 3,000.00

Fibroblast Growth Factor 21 (FGF21) - Drugs in Development, 2021 SUMMARY Fibroblast Growth Factor 21 (FGF21) - Drugs in Development, 2021 provides in depth analysis on Fibroblast Growth Factor 21 (FGF...

April 2021 30 pages

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Drugs in Development, 2021

US$ 3,000.00

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Drugs in Development, 2021 SUMMARY Fibroblast Growth Factor Receptor 2 (Ke...

April 2021 85 pages

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Drugs in Development, 2021

US$ 3,000.00

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Drugs in Development, 2021 SUMMARY Fibroblast Growth Factor Receptor 3 (Tyro...

April 2021 80 pages

Fibroblast Growth Factor Receptor (FGFR or EC 2.7.10.1) - Drugs in Development, 2021

US$ 3,000.00

Fibroblast Growth Factor Receptor (FGFR or EC 2.7.10.1) - Drugs in Development, 2021 SUMMARY Fibroblast Growth Factor Receptor (FGFR or EC 2.7.10.1) - Drugs in Development, 2021 provides in depth anal...

April 2021 45 pages

Fibronectin (Cold Insoluble Globulin or FN1) - Drugs in Development, 2021

US$ 3,000.00

Fibronectin (Cold Insoluble Globulin or FN1) - Drugs in Development, 2021 SUMMARY Fibronectin (Cold Insoluble Globulin or FN1) - Drugs in Development, 2021 provides in depth analysis on Fibronectin (C...

April 2021 30 pages

Fibrosis (Musculoskeletal) - Drugs in Development, 2021

US$ 2,500.00

Fibrosis (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Fibrosis (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Fibrosis pipeline landscape. The report provides com...

April 2021 250 pages

Flavivirus Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Flavivirus Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Flavivirus Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Flavivirus Infection...

April 2021 30 pages

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Drugs in Development, 2021

US$ 3,000.00

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Drugs in Development, 2021 SUMMARY Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Drugs in Development, 2021 provides in depth analysis on Focal Adhesion Kin...

April 2021 45 pages

Focal Segmental Glomerulosclerosis (FSGS) (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021

US$ 2,000.00

Focal Segmental Glomerulosclerosis (FSGS) (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021 SUMMARY Focal Segmental Glomerulosclerosis (FSGS) (Genito Urinary System And Sex Hormone...

April 2021 65 pages

Follicle Stimulating Hormone Receptor (Follitropin Receptor or FSHR) - Drugs in Development, 2021

US$ 3,000.00

Follicle Stimulating Hormone Receptor (Follitropin Receptor or FSHR) - Drugs in Development, 2021 SUMMARY Follicle Stimulating Hormone Receptor (Follitropin Receptor or FSHR) - Drugs in Development, 2...

April 2021 60 pages

Follicular Lymphoma (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Follicular Lymphoma (Oncology) - Drugs in Development, 2021 SUMMARY Follicular Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Follicular Lymphoma pipeline landscape. The...

April 2021 375 pages

Follicular Thyroid Cancer (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Follicular Thyroid Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Follicular Thyroid Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Follicular Thyroid Cancer pipeli...

April 2021 50 pages

Food Allergy (Immunology) - Drugs in Development, 2021

US$ 2,000.00

Food Allergy (Immunology) - Drugs in Development, 2021 SUMMARY Food Allergy (Immunology) - Drugs in Development, 2021 provides an overview of the Food Allergy pipeline landscape. The report provides c...

April 2021 60 pages

Forkhead Box Protein P3 (Scurfin or FOXP3) - Drugs in Development, 2021

US$ 3,000.00

Forkhead Box Protein P3 (Scurfin or FOXP3) - Drugs in Development, 2021 SUMMARY Forkhead Box Protein P3 (Scurfin or FOXP3) - Drugs in Development, 2021 provides in depth analysis on Forkhead Box Prote...

April 2021 35 pages

Fuchs Endothelial Corneal Dystrophy (FECD) (Ophthalmology) - Drugs in Development, 2021

US$ 2,000.00

Fuchs Endothelial Corneal Dystrophy (FECD) (Ophthalmology) - Drugs in Development, 2021 SUMMARY Fuchs Endothelial Corneal Dystrophy (FECD) (Ophthalmology) - Drugs in Development, 2021 provides an over...

April 2021 35 pages

Fungal Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Fungal Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Fungal Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Fungal Infections pipeline l...

April 2021 130 pages

Filters

Clear all